This clinical trial is focused on studying the effects of the medication tacrolimus on patients undergoing hemodialysis, which is a treatment for kidney failure that helps filter waste and water from the blood. The purpose of the study is to evaluate how tacrolimus affects the way the body processes carbohydrates, which are sugars and starches that the body uses for energy, in patients who are on dialysis and awaiting a kidney transplant.

Participants in the study will receive tacrolimus orally, which means they will take it by mouth. The study will last for a period of 14 days. During this time, researchers will monitor changes in the participants’ glycemic profile, which refers to the levels of sugar in the blood. The goal is to determine if there is a significant change in blood sugar levels from the start of the treatment to the end of the 14-day period.

This study is important for understanding how tacrolimus might affect blood sugar levels in patients who are on dialysis and preparing for a kidney transplant. The findings could help improve the management of these patients’ conditions and provide insights into the safe use of tacrolimus in this specific group of patients.